Kiadis Pharma receives IND approval from FDA to start pivotal clinical trial with ATIR™
Jul 8th 2010
Biopharmaceutical Company Kiadis Pharma announced today that it has received approval for its Investigational New Drug (IND) application with the US...
read more 
(NL version)
(NL version)
Kiadis Pharma Provides ATIR™ Update: Two Year Follow-Up Data Show No Cases of Transplant Related Mortality - FDA grants ATIR™ Orphan Drug Status as a Medicinal Cell Based Therapy to Reduce Transplant Related Mortality
Apr 28th 2010
Kiadis Pharma today provided an update on its cell therapy product ATIR™ developed for mismatched bone marrow transplants.
ATIR™ continues to show... read more (NL version)
ATIR™ continues to show... read more
(NL version)
- Kiadis Pharma announces enrollment of first patients in a multinational registration study for ATIR™ - Nov 29th 2009 (NL)
- Promising clinical data from Kiadis Pharma’s lead product ATIR™ will be presented at the 51st American Society of Hematology’s (ASH) Annual Meeting - Nov 5th 2009 (NL)
- Kiadis Pharma reports ATIR™ clinical data, further supporting its potential in mismatched bone marrow transplantations - ATIR™ data presented at the annual EBMT Presidential Symposium - Apr 8th 2009 (NL)
- Kiadis Pharma’s lead investigator presents results ATIR™ clinical trial at the BMT tandem meeting - Feb 6th 2009 (NL)
- Kiadis Pharma appoints Dr. Maarten Egeler, MD PhD as Chief Medical Officer - Jan 6th 2009 (NL)
1096 EG Amsterdam
The Netherlands
t +31 (0)20 314 02 50
f +31 (0)20 314 02 51